Patrick Plésiat

3.7k total citations · 1 hit paper
25 papers, 2.0k citations indexed

About

Patrick Plésiat is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Medicine. According to data from OpenAlex, Patrick Plésiat has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Epidemiology and 8 papers in Molecular Medicine. Recurrent topics in Patrick Plésiat's work include Antibiotic Resistance in Bacteria (8 papers), Cystic Fibrosis Research Advances (8 papers) and Bacterial Genetics and Biotechnology (4 papers). Patrick Plésiat is often cited by papers focused on Antibiotic Resistance in Bacteria (8 papers), Cystic Fibrosis Research Advances (8 papers) and Bacterial Genetics and Biotechnology (4 papers). Patrick Plésiat collaborates with scholars based in France, United States and Canada. Patrick Plésiat's co-authors include Hiroshi Nikaido, Xian-Zhi Li, Katy Jeannot, Cédric Muller, Didier Hocquet, Catherine Neuwirth, Catherine Llanes, Christelle Vogne, Philippe Bénas and Isabelle Broutin and has published in prestigious journals such as PLoS ONE, Clinical Microbiology Reviews and Scientific Reports.

In The Last Decade

Patrick Plésiat

24 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

2015 1.1k citations Patrick Plésiat et al. profile →

Peers

Countries citing papers authored by Patrick Plésiat

Since Specialization

Citations

This map shows the geographic impact of Patrick Plésiat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Plésiat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Plésiat more than expected).

Fields of papers citing papers by Patrick Plésiat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Plésiat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Plésiat. The network helps show where Patrick Plésiat may publish in the future.

Co-authorship network of co-authors of Patrick Plésiat

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Plésiat. A scholar is included among the top collaborators of Patrick Plésiat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Plésiat. Patrick Plésiat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1,2,3-Triazole‑gold(I)-triethylphosphine derivatives of nutrients as new antimicrobials against antibiotic resistant Gram-positive pathogens 2025 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Françoise Hoegy, (unknown), Jean‐Marie Contreras, Christophe Morice, Patrick Plésiat, Gaëtan L. A. Mislin	0
2	Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients 2021 ·Journal of Cystic Fibrosis ·Vincent Le Moigne, Anne‐Laure Roux, (unknown), (unknown), Agnès Ferroni, Oana Dumitrescu, Gérard Lina, Jean‐Philippe Bouchara, Patrick Plésiat, Jean‐Louis Gaillard, (unknown), Geneviève Héry-Arnaud, Jean‐Louis Herrmann	7
3	Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort 2020 ·Open Forum Infectious Diseases ·Núria Fernández-Hidalgo, Amal Gharamti, María Luisa Aznar, Benito Almirante, Mohamad Yasmin, Cláudio Querido Fortes, Patrick Plésiat, Thanh Doco‐Lecompte, Hussien Rizk, Dannah Wray, Cristiane da Cruz Lamas, Emanuele Durante‐Mangoni, Pierre Tattevin, Ulrika Snygg‐Martin, Margaret M. Hannan, Vivian H. Chu, Zeina A. Kanafani	10
4	Chryso-lactams:Gold(I) derivatives of ampicillin with specific activity against Gram-positive pathogens 2020 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Jean‐Marie Contreras, Christophe Morice, (unknown), Isabelle J. Schalk, Patrick Plésiat, Gaëtan L. A. Mislin	10
5	Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry 2019 ·PLoS ONE ·(unknown), (unknown), Clémence Dehillotte, Lydie Lemonnier, Alicia Guillien, Bruno Degano, Marie‐Laure Dalphin, Jean‐Charles Dalphin, Patrick Plésiat	14
6	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic 2017 ·Scientific Reports ·Hussein Chalhoub, Daniel Pletzer, Helge Weingart, Yvonne Braun, Michael M. Tunney, J.S. Elborn, Hector Rodriguez‐Villalobos, Patrick Plésiat, Barbara C. Kahl, Olivier Denis, Mathias Winterhalter, Paul M. Tulkens, Françoise Van Bambeke	34
7	Drug Susceptibility Testing by Dilution Methods 2014 ·Methods in molecular biology ·Katy Jeannot, Patrick Plésiat	1
8	Development of a Multiple-Locus Variable-Number Tandem-Repeat Typing Scheme for Genetic Fingerprinting of Burkholderia cenocepacia and Application to Nationwide Epidemiological Analysis 2014 ·Journal of Clinical Microbiology ·Christine Segonds, Michelle Thouverez, Antoine Barthe, Nadège Bossuet‐Greif, (unknown), Patrick Plésiat, Gilles Vergnaud, G. Chabanon, Christine Pourcel	5
9	Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa 2013 ·Antimicrobial Agents and Chemotherapy ·(unknown), Cédric Muller, Laura Monlezun, Philippe Bénas, Isabelle Broutin, Katy Jeannot, Patrick Plésiat	88
10	A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and β-Lactams in Pseudomonas aeruginosa 2010 ·Antimicrobial Agents and Chemotherapy ·Cédric Muller, Patrick Plésiat, Katy Jeannot	168
11	Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli 2009 ·Journal of Cystic Fibrosis ·Christine Segonds, Michelle Thouverez, Dominique Grenet, Patrick Plésiat, G. Chabanon	2
12	Microbiological and Epidemiological Features of Clinical Respiratory Isolates of Burkholderia gladioli 2009 ·Journal of Clinical Microbiology ·(unknown), (unknown), Michelle Thouverez, D. Grenet, Alain Le Coustumier, Patrick Plésiat, G. Chabanon	43
13	Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality 2006 ·European Heart Journal ·Xavier Duval, François Alla, Thanh Doco‐Lecompte, Vincent Le Moing, François Delahaye, Jean‐Luc Mainardi, Patrick Plésiat, M. Célard, Bruno Hoen, C. Leport	37
14	Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa 2005 ·Journal of Antimicrobial Chemotherapy ·(unknown), Didier Hocquet, Katy Jeannot, P. Chavanet, Patrick Plésiat	30
15	Clinical Strains of Pseudomonas aeruginosa Overproducing MexAB-OprM and MexXY Efflux Pumps Simultaneously 2004 ·Antimicrobial Agents and Chemotherapy ·Catherine Llanes, Didier Hocquet, Christelle Vogne, (unknown), Catherine Neuwirth, Patrick Plésiat	222
16	Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit 2001 ·Intensive Care Medicine ·Edgar Tissot, Marie-Christine Woronoff-Lemsi, C. Cornette, Patrick Plésiat, Micheline Jacquet, Gilles Capellier	15
17	Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer 2000 ·Medical and Pediatric Oncology ·Pascal Chastagner, Emmanuel Plouvier, (unknown), Patrick Plésiat, Alain Lozniewski, D. Sommelet	15
18	Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis 2000 ·American Journal of Infection Control ·(unknown), (unknown), N. Marty, A Sardet, P D’Athis, F. Brémont, Marie‐Laure Dalphin, Patrick Plésiat, G. Rault, (unknown), S. Dominique, (unknown), J. Derelle, M. Blech, M Roussey, M. Perrin, A. Sautegeau	55
19	Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers 1997 ·Journal of Clinical Microbiology ·Christine Segonds, Édouard Bingen, G. Couetdic, (unknown), N. Brahimi, N. Marty, Patrick Plésiat, Y Michel-Briand, G. Chabanon	29
20	Persistence of Pseudomonas aeruginosa strains in seven cystic fibrosis patients followed over 20 months. 1993 ·PubMed ·C. Godard, Patrick Plésiat, Y Michel-Briand	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact